126.52 0.00 (0.00%)
After hours: 4:28PM EDT
|Bid||126.70 x 800|
|Ask||126.71 x 900|
|Day's Range||126.32 - 131.46|
|52 Week Range||90.64 - 141.25|
|Beta (3Y Monthly)||0.24|
|PE Ratio (TTM)||45.19|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||1.56 (1.20%)|
|1y Target Est||123.37|
ResMed (RMD) (RMD.AX) today introduced AirFit N30, the world’s first tube-down nasal cradle CPAP mask with a front-facing tube – a brand-new option for sleep apnea treatment. ResMed’s lightest mask yet, AirFit N30 features an adjustable elastic headgear, plus a nasal cradle cushion that sits under the nasal bridge, eliminating soreness in that area. Together, these innovations help make starting and staying on CPAP therapy easier than ever for more of the 936 million people worldwide living with sleep apnea.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
The survey highlights a reason for optimism that the markets for digital health technology will only continue to grow. The survey of a nationally representative sample of 3,000 Americans, conducted in partnership with Edelman Intelligence, revealed that the use of – and confidence in – remote digital health technology is widespread: 56% of those surveyed currently monitor their health with at least one digital data collection tool. Perhaps more surprising, remote digital health technology seems to have deepened people’s connection with their physicians rather than distanced them from one another.
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of June 28. The results of that effort will be put on display in this article, as […]
Cerner Corporation (CERN), a global health platform and innovation company, and ResMed (NYSE: RMD, ASX: RMD), a world-leading digital health company, today announced a new collaboration agreement to help providers make more informed treatment decisions, control costs and deliver seamless care across health systems to the home. To address this trend, Cerner designated ResMed’s Brightree Home Health and Hospice platform as its preferred solution in the space to integrate with its Cerner Millennium® electronic health record (EHR).
ResMed today announced it plans to release financial and operational results for the first quarter of fiscal year 2020 on Thursday, October 24, 2019, after the New York Stock Exchange closes.
With more than 10 million cloud-connected CPAP and other breathing devices on the market, CEO Mick Farrell completely understands why patients are wary about letting those devices send data to the cloud.
ResMed (NYSE: RMD, ASX: RMD) today announced that CEO Mick Farrell will ring The Opening Bell® at the New York Stock Exchange (NYSE) on Monday, September 30, 2019 at 9:30 a.m. ET. Farrell will be joined on the bell podium with other members of the ResMed management team to celebrate 20 years of being listed on the NYSE and to commemorate ResMed’s 30th anniversary. Founded in 1989, ResMed began as ResCare, a management buy-out of sleep apnea technology from Baxter Healthcare.
CEO of Resmed Inc (30-Year Financial, Insider Trades) Michael J. Farrell (insider trades) sold 6,651 shares of RMD on 09/09/2019 at an average price of $137.38 a share. Continue reading...
ResMed Inc (RMD) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. ResMed Inc is a part of the healthcare sector. Continue reading...
Mick Farrell, ResMed CEO, joined Yahoo Finance from the New York Stock Exchange as the company celebrates its 20th year as a publicly traded company.